GlassScriptPhysician profile
James K Ellis
NPI 1982792750
$113,066.68
in general payments reported to CMS, 2019-2025
85 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,045 · 2020: $2,020 · 2021: $4,315 · 2022: $26K · 2023: $23K · 2024: $22K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $18K · Consulting Fee: $4,493 · Travel and Lodging: $1,472 · Education: $378 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,882.50 |
| Food and Beverage | $17,784.06 |
| Consulting Fee | $4,493.00 |
| Travel and Lodging | $1,471.59 |
| Education | $377.63 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $72,580.37 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Incyte Corporation | $4,793.69 | 2019-2025 | Jakafi, Monjuvi, Jakafi |
| Sobi, INC | $4,667.19 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,498.39 | 2019-2025 | |
| Kite Pharma, INC. | $2,405.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $2,295.47 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $2,111.48 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $2,014.30 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $1,269.33 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,126.10 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $1,049.50 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Genentech USA, INC. | $975.22 | 2019-2025 | Polivy, Phesgo, Lunsumio |
| Bayer Healthcare Pharmaceuticals INC. | $891.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $769.11 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Coherus Oncology, INC. | $740.67 | 2020-2023 |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $667.51 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Astellas Pharma US INC | $603.62 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Genzyme Corporation | $597.15 | 2019-2025 | |
| Eisai INC. | $583.35 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $578.85 | 2019-2023 | Imbruvica |
| Seagen INC. | $538.60 | 2019-2023 | Tukysa, Adcetris |
| Novocure INC. | $530.44 | 2024-2025 | Optune, Optune Lua (Novottf-200t), Optune Gio |
| Exelixis INC. | $509.82 | 2019-2025 | Cabometyx |
| Abbvie INC. | $490.80 | 2019-2025 | |
| Amgen INC. | $441.94 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Regeneron Healthcare Solutions, INC. | $437.80 | 2019-2025 | Libtayo |
| Puma Biotechnology, INC. | $431.52 | 2019-2025 | |
| Gilead Sciences, INC. | $400.60 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $399.73 | 2019-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $368.89 | 2020-2025 | Xpovio |
| Tempus Ai, INC | $347.14 | 2024 | Xt Cdx |
| Array Biopharma INC | $298.65 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Lilly USA, LLC | $281.33 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $273.39 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Adaptive Biotechnologies Corporation | $243.17 | 2022-2025 | Clonoseq |
| Clovis Oncology, INC. | $218.39 | 2019-2020 | |
| Beigene USA, INC. | $209.11 | 2020-2023 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $191.87 | 2021-2025 | |
| Stemline Therapeutics INC. | $181.39 | 2023-2025 | Orserdu |
| Epizyme, INC. | $169.38 | 2020-2021 | |
| Caris Mpi, INC. | $158.12 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $151.11 | 2020-2022 | |
| Emd Serono, INC. | $148.95 | 2019-2025 | |
| Tg Therapeutics, INC. | $145.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $120.45 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $116.50 | 2023-2025 | Zepzelca |
| Mirati Therapeutics, INC. | $115.91 | 2023-2024 | Krazati |
| Morphosys, US INC. | $115.30 | 2021-2024 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.67 | 2019-2025 | Gilotrif |
| Taiho Oncology, INC. | $97.15 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $93.75 | 2024-2025 | Sylvant, Enjaymo |
| Myovant Sciences INC. | $92.65 | 2021-2022 | |
| Springworks Therapeutics, INC. | $92.57 | 2025 | Ogsiveo |
| Progenics Pharmaceuticals, INC. | $90.41 | 2022-2024 | |
| Kyowa Kirin, INC. | $88.33 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $87.81 | 2023-2025 | Sancuso |
| Pharmacosmos Therapeutics INC. | $73.98 | 2024-2025 | Cosela, Monoferric |
| G1 Therapeutics, INC. | $69.98 | 2022-2023 | Cosela |
| Dova Pharmaceuticals | $67.75 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $66.73 | 2019-2024 | Tavalisse, Rezlidhia |
| Sumitomo Pharma America, INC. | $65.85 | 2023-2025 | Orgovyx |
| Foundation Medicine, INC. | $64.06 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $60.49 | 2024 | |
| Intuitive Surgical, INC. | $55.27 | 2023 | |
| Adc Therapeutics America, INC. | $53.75 | 2022-2024 | |
| Cti Biopharma Corp. | $50.07 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $40.45 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $35.92 | 2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $32.83 | 2023-2024 | Precisetumor, Myrisk |
| Teva Pharmaceuticals USA, INC. | $30.03 | 2019 | |
| Acceleron Pharma, INC. | $28.50 | 2021 | |
| Janssen Scientific Affairs, LLC | $28.22 | 2019 | |
| Shield Therapeutics INC | $27.26 | 2024 | |
| Sun Pharmaceutical Industries INC. | $25.48 | 2024 | |
| Tesaro, INC. | $24.47 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.01 | 2025 | Danziten |
| Acrotech Biopharma INC. | $20.58 | 2024 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $17.47 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.26 | 2023 | Empaveli |
| Servier Pharmaceuticals LLC | $16.75 | 2022 | |
| Sirtex Medical INC | $16.54 | 2019 | |
| Secura Bio, INC. | $14.59 | 2024 | Copiktra |
| Verastem, INC. | $14.10 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $13.75 | 2019 | |
| Immunomedics, INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.